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Gliomas constitute 40–67% of primary neoplasms of the central
nervous system. Despite advances in therapy, the prognosis for the
most malignant gliomas remains poor with post-treatment survival
times of often less than a year (Black, 1991; Hildebrand et al,
1997). Low grade gliomas are associated with longer median
survival, but a proportion progress to anaplastic tumours or
glioblastomas accompanied by sequential acquisition of genetic
alterations (Black, 1991; Ohgaki et al, 1995; Louis, 1997). While
many of the molecular genetic events involved in the histogenesis
of gliomas have already been characterized (reviewed in Louis,
1997), identification of those events associated with the transition
of astrocytic tumours from low grade to higher grade is important
in the quest for improved diagnosis and future therapeutic
advances.
Loss of all or part of chromosome 10q occurs in approximately
70% of glioblastomas but only rarely in low grade gliomas (Bigner
et al, 1988; Steck et al, 1995; Rasheed et al, 1995). On the basis of
cytogenetic and loss of heterozygosity (LOH) studies, one or more
tumour suppressor genes involved in the development of advanced
cancers has been postulated within chromosome 10q (Bigner et al,
1988; Karlbom et al, 1993; Steck et al, 1995; Rasheed et al, 1995;
Sonoda et al, 1996; Böstrom et al, 1998). Recent investigations
have led to the isolation of a candidate tumour suppressor gene,
PTEN (MMAC1), located at chromosome 10q23.3 (Li et al, 1997;
Steck et al, 1997), which encodes a protein tyrosine phosphatase
(Li and Sun, 1997) and has homology to tensin and auxilin (Li et
al, 1997; Myers and Tonks, 1997; Steck et al, 1997). Germ-line
mutations in the PTEN gene have been found in a variety of inher-
itable disorders associated with formation of multiple benign
tumours and an increased incidence of malignant disease (Liaw et
al, 1997; Lynch et al, 1997; Marsh et al, 1997; Nelen et al, 1997).
LOH at the PTEN locus and mutations in the PTEN gene have
been reported in a wide variety of sporadic cancers, including
prostate (Cairns et al, 1997; Suzuki et al, 1998), primary breast
tumours (Rhei et al, 1997), malignant melanomas (Guldberg et al,
1997) and endometrial carcinomas (Tashiro et al, 1997; Risinger et
al, 1997). In the gliomas investigated so far, 16% of anaplastic
astrocytomas and 26% of glioblastomas had PTEN mutations, but
none have been found in low grade gliomas (Li et al, 1997; Liu et
al, 1997; Rasheed et al, 1997; Sakurada et al, 1997; Steck et al,
1997; Wang et al, 1997; Böstrom et al, 1998; Chiariello et al,
1998). Thus, genetic alterations in the PTEN gene may be
involved in the progression of gliomas to advanced disease.
Investigations of mutation in the PTEN gene in gliomas have so
far been restricted to DNA or RNA extracted from snap frozen
tumour. The results obtained from such studies may not correlate
precisely with histology and are inappropriate for the tiny amounts
of processed biopsy material on which diagnosis is often based.
Microdissection of regions of known histology increases the
neoplastic cell population in the samples for analysis and allows
mutation to be related accurately to histological grade. This tech-
nique can be applied to diagnostic biopsy material.
In order to investigate further the relationship of mutation in the
PTEN gene to the histological grade of gliomas, we have devel-
oped methods for PTEN mutation detection by direct sequence
analysis in samples microdissected from archival, formalin-fixed,
paraffin-embedded tissues. We have investigated the incidence of
mutation in the PTEN gene in a series of 19 low grade [World
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Health Organization (WHO) grades I and II] and 27 high grade
gliomas (13 anaplastic astrocytomas WHO grade III, 14 glio-
blastomas WHO grade IV) and relate our findings to the histology
of the samples analysed.
MATERIALS AND METHODS
Tumour samples
Formalin-fixed paraffin-embedded blocks of gliomas, diagnosed
from 1986 to 1997, were obtained from the archives at the
Neurosurgery Centre, Walton Hospital, Liverpool, UK. Cases
selected for study were either biopsies or surgical resections, had
clinical information available, and had both tumour and normal
brain tissue present for analysis. None of the patients had
chemotherapy prior to surgery or biopsy. The histological diag-
nosis of all cases was re-reviewed (MLR) and, where necessary,
immunocytochemistry using antibodies to GFAP, a actin, Factor
VIII and CD 34 was carried out to assist accurate histopathological
diagnosis. Tumours were classified according to WHO criteria
(Kleihues et al, 1993).
Microdissection
Microdissection was used to enrich the population of either normal
or tumour cells for analysis. Prior to microdissection, a 5 mM serial
section stained with haematoxylin and eosin was examined by a
pathologist (MLR) and regions of tissue selected for analysis. The
Table 1 Clinical information
Case Age at Prior Survival WHO WHO Sequence
number Gender diagnosis Location therapy (months) classification grade variant
1 Male 16 Supratentorial No 144+ Astrocytoma II No
2 Male 65 Supratentorial No # Astrocytoma II No
3 Male 68 Supratentorial No 39 Astrocytoma II No
4 Female 61 Supratentorial No 25 Astrocytoma II No
5 Female 53 Supratentorial No 56+ Astrocytoma II No
6 Female 40 Supratentorial No 34+ Astrocytoma II No
7 Female 48 Supratentorial No 29+ Astrocytoma II No
8 Female 45 Supratentorial No 30+ Astrocytoma II No
9 Male 30 Supratentorial No 20 Astrocytoma II No
10 Male 37 Supratentorial No 25+ Astrocytoma II No
11 Male 39 Supratentorial No 17+ Astrocytoma II No
12 Male 68 Supratentorial No 14 Astrocytoma II No
13 Male 55 Supratentorial No 20+ Astrocytoma II No
14 Female 13 Infratentorial No 38+ Astrocytoma (pilocytic) I No
15 Female 57 Infratentorial No 33+ Astrocytoma (pilocytic) I No
16 Female 7 Supratentorial Yes 42+ Astrocytoma II No
17 Female 33 Supratentorial No 58+ Oligoastrocytoma II No
18 Female 26 Supratentorial No 19+ Oligoastrocytoma II No
19 Male 64 Supratentorial No 37+ Oligodendroglioma II No
20 Male 23 Supratentorial No 15 Anaplastic astrocytoma III No
21 Female 41 Supratentorial No 13 Anaplastic astrocytoma III Yes
22 Female 73 Supratentorial No 3 Anaplastic astrocytoma III No
23 Male 62 Supratentorial No 2 Anaplastic astrocytoma III Yes
24 Male 66 Supratentorial No 1 Anaplastic astrocytoma III No
25 Male 71 Supratentorial No 12 Anaplastic astrocytoma III No
26 Male 44 Supratentorial No 33+ Anaplastic astrocytoma III No
27 Female 48 Supratentorial No 27+ Anaplastic astrocytoma III No
28 Male 60 Supratentorial No 12+ Anaplastic astrocytoma III No
29 Male 50 Supratentorial No 12 Anaplastic astrocytoma III Yes
30 Male 51 Supratentorial No 1 Anaplastic astrocytoma III Yes
31 Female 32 Supratentorial No 46+ Anaplastic astrocytoma* III No
32 Male 45 Supratentorial No 0.2 Anaplastic astrocytoma* III No
33 Female 62 Supratentorial No 14 Glioblastoma IV No
34 Female 76 Supratentorial No # Glioblastoma IV No
35 Female 61 Supratentorial No 11 Glioblastoma IV Yes
36 Female 79 Supratentorial No 5 Glioblastoma IV No
37 Female 59 Supratentorial No 10 Glioblastoma IV No
38 Female 36 Supratentorial No 12 Glioblastoma IV Yes
39 Male 62 Supratentorial No 2 Glioblastoma IV No
40 Female 65 Supratentorial No 1 Glioblastoma IV Yes
41 Female 66 Supratentorial No 13 Glioblastoma IV Yes
42 Female 43 Supratentorial No 9 Glioblastoma IV Yes
43 Male 49 Supratentorial No 19 Glioblastoma IV Yes
44 Male 27 Supratentorial No 7 Glioblastoma** IV No
45 Male 57 Supratentorial Yes 22 Glioblastoma IV No
46 Male 35 Supratentorial Yes 35 Glioblastoma IV No
*Gemistocytic; **giant cell. Survival details: + = patient alive, # = patient lost to follow-up.1544 MPA Davies et al
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marked slide was used to guide microdissection of the chosen
histological regions from three serial 10 mM sections, dewaxed
through xylene and graded alcohols to water and stained with 0.1%
toluidine blue. Microdissection was carried out using a stereo-
dissecting microscope and an electrolytically polished tungsten
needle controlled by a micromanipulator (Going et al, 1996).
Tissue fragments of 0.01–0.15 mm2 were microdissected avoiding,
where possible, blood vessels and regions of necrosis. These frag-
ments were collected in 12.5-ml buffer (10 mM Tris-HCl pH 8.0,
1m M EDTA). Multiple fragments (up to 15 samples) within the
same low power field (´ 50) were pooled and digested at 37°C
for 72 h following the addition of an equal volume of buffer con-
taining 2 mg ml–1 proteinase K and 2.0% Tween 20. This procedure
created a tissue extract of up to 300 ml representing 0.002–0.02
mm2 of tissue ml–1. Proteinase K was inactivated by boiling for 15
min. Extracts were stored at –20°C. Digitized computer images
were archived before and after microdissection. These images and
haematoxylin and eosin stains of the microdissected sections and
serial sections were used for pathological review.
PCR amplification
Polymerase chain reaction (PCR) amplification was performed in
20-ml or 40-ml reaction volumes for first round or second round
reactions, respectively, containing 1 ´ amplitaq PCR buffer, 200 mM
each dNTP, 1 mM each primer (designed for use with paraffin-
embedded tissues using Oligo software) and 0.1 units Amplitaq
Gold (Perkin Elmer). Two-microlitre aliquots of tissue extract were
used as target in first round reactions and 2 ml of the first round
reaction were taken into second round reactions. 1.5 mM magne-
sium chloride (MgCl2) was used for amplification of exons 1, 2 and
8b, while 2.5 mM MgCl2 was used for exon 8a. All other PTEN
exons required 2 mM MgCl2. For some samples, nested reverse
primers for exons 4 and 5a were used in the second round. PTEN
exons were amplified with the following PCR conditions: –94°C
for 10 min followed by 35 cycles (exons 1, 2, 3, 4, 5b, 6, 7, 8b) or
38 cycles (exons 5a, 8a, 9) of 94°C for 30 s, 56°C for 30 s, 72°C for
30 s, then 72°C extension for 10 min. In the second round the same
cycling conditions were used but for 35–40 cycles.
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Figure 1 Microdissection of samples for mutation analysis. (A, B) Case 1 – an astrocytoma WHO grade II; (A) haematoxylin and eosin stain of 5 mM serial
section not microdissected (bar = 500 mM); (B) haematoxylin and eosin stain of 10 mM section after microdissection (bar = 500 mM). (C, D) Case 20 – an
anaplastic astrocytoma WHO grade III; (C) hematoxylin and eosin stain of 10 mm section after microdissection (bar = 1 mm); (D) same section at higher
magnification illustrating microdissection to avoid vessels (bar = 250 mm). Illustrations are video captured computer generated images. M – tissue area
microdissected; V – vascular proliferation N – normal tissue with infiltrating tumour; arrow – region of tissue containing blood vesselsPTEN mutation in gliomas 1545
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Mutation detection
Sequence analysis of PCR products was carried out blind, without
knowledge of the histological grading of the samples being
analysed. The nucleotide sequence of each PCR product was
determined in the forward and reverse directions by cycle-
sequencing using dRhodamine dye-terminator kits (ABI) with the
primers used for PCR. Sequencing reactions were purified by
ethanol precipitation prior to electrophoresis using an ABI 377.
Sequence data analysis used Factura and Sequence Navigator soft-
ware (ABI). Sequence variations detected in both forward and
reverse directions were confirmed by analysis of a second inde-
pendent PCR product amplified from the same tissue extract. DNA
amplified from normal brain tissue was analysed to determine
whether the observed sequence variation was acquired.
Microsatellite analysis
Normal and tumour tissue extracts were analysed for allelic imbal-
ance in chromosome 10q using polymorphic markers D10S1687,
D10S583, AFMA086WG9 and D10S2491 (Cairns et al, 1997;
Rasheed et al, 1997; Steck et al, 1997). Two microlitres of tissue
extract was used in 10-ml PCR reactions containing 1 ´ amplitaq
PCR buffer, 200 mM each dNTP, 1.5 mM MgCl2 or [2 mM MgCl2
for D10S1687], 0.1 mM each primer and 0.05 units Amplitaq Gold
(Perkin Elmer). PCR conditions were: –94°C for 10 min followed
by 48 cycles of 94°C for 30 s, 56°C [or 60°C for D10S1687] for
30 s, 72°C for 30 s, followed by 72°C extension for 10 min. The 5´
ends of reverse primers were labelled with fluorescent FAM. One
microlitre of PCR products was mixed with 0.33 ml ROX-350 size
standard (Perkin Elmer) and 2 ml formamide-loading buffer.
Samples were denatured immediately prior to gel loading by
heating to 96°C for 5 min, followed by snap-chilling in an ice-
water bath. Analysis was performed using denaturing (6 M urea)
5.5% acrylamide gels on an ABI-377 Fluorescent DNA Analyser
and loading 0.75 ml per lane. Results were analysed using
GeneScan software. In informative cases, allelic loss was scored if
the area under one allele peak was reduced to less than 30% of its
value in the normal tissue extract (relative to the other allele).
Statistical analysis
Data were analysed using Fisher–Irwin Exact test.
RESULTS
Clinical information for the cases analysed in this study is given in
Table 1. The cases studied were predominantly adult, astrocytic,
supratentorial tumours obtained prior to therapy (13 low grade and
25 high grade). For tumour samples, the areas chosen for microdis-
section were most representative of the histological grading of the
tumour. Microdissected samples from anaplastic astrocytomas and
glioblastomas were judged, by a pathologist, to be > 80% and > 90%
tumour cells, respectively. Tumour samples from astrocytomas and
other low grade tumours were as pure as could be achieved from the
tissues available. Samples analysed from all low grade cases were
considered to contain approximately 80% tumour cells, except those
from cases 2 and 3 which contained approximately 20–30% and
50% neoplastic cells, respectively. For normal tissue, normal brain
most free of infiltrating tumour cells was selected. Figure 1 shows
examples of microdissection.
Previous studies, involving amplification of the b-globin gene
from microdissected samples (< 1 mm2) isolated from a series of
archival brain tumours, from the Neurosurgery Centre, Walton
Hospital, Liverpool, UK, have shown that PCR amplification was
more efficient with amplicons less than 275 bp. PTEN primers for
amplicons < 275 bp were designed (Table 2) from the sequence
obtained by amplifying human placental genomic DNA using the
Table 2 Primers for PCR amplification of the PTEN gene from formalin-
fixed, paraffin-embedded tissues
Exon Forward primer Reverse primer
1 caagtccagagccatttcc cccaacgttctaagagagtga
2 ttcttttagtttgattgctg gtatctttttctgtggcttag
3 ctgtcttttggtttttctt caagcagataactttcactta
4 tataaagattcaggcaatgtt ctcgataatctggatgactc
*cagtctatcgggtttaagtta
5a ttgttaattaaaaattcaagag gcacatatcattacaccagt
*cctttccagctttacagt
5b tgaccaatggctaagtgaa aaaagaaacccaaaatctgtt
6 cccagttaccatagcaat taagaaaactgttccaataca
7 ttgacagttaaaggcatttc cttattttggatatttctccc
8a ttcatttctttttcttttcttt ggttggctttgtctttatt
8b ccaggaccagaggaaac cacatacatacaagtcaccaa
9 agtcatatttgtgggtttt ttattttcatggtgttttatc
*Nested primers.
Table 3 PTEN sequence variants
Case Codon Exon Base* Change Effect Acquired
21 76 4 226–228 Del TAT Delete Tyr YES
23 173 6 519 G to A Arg to His YES
29 Non-coding Intron 2 Exon 3–34 A to G None? ND
30 131 5 392 C to A Thr to Asn YES
35 Non-coding Intron 3 Exon 3 +5 G to A Splice mutation YES
38 Non-coding Intron 3 Exon 4–39 A to G None? NO
38 98 5 294 A to G Silent ND
40 ? 5 ? Deletion/insertion Deletion/insertion YES
41 27 2 80 A to C Tyr to Ser YES
42 171 6 511 C to T Gln to stop YES
43 42 2 125 T to C Leu to Pro YES
*Numbering of nucleotides according to Li et al 1997 (GenBank accession no. U93051). ND = not determined.1546 MPA Davies et al
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PTEN primer set published by Steck et al (1997). For analysis of
the PTEN gene, 11 PCR reactions were required to cover the
coding sequence of the nine exons.
Direct sequence analysis of PTEN PCR products amplified from
microdissected tissue samples was successful for all cases investi-
gated. Sequence data were obtained for 100% of exon sequence
and flanking splice sites in all 46 cases. Results obtained are
shown in Tables 1 and 3, and in Figure 2.
Of the 11 confirmed genetic variants described in ten tumours,
eight were acquired by the tumour, being absent from the normal
tissue. Additionally, these mutations are likely to affect the
encoded protein (Table 3); four are missense mutations, one is an
in-frame single codon deletion, one is a nonsense mutation, one is
a non-coding, intronic mutation proximal to the splice site, and one
(in case 40) is a putative deletion involving part of exon 5/intron 5.
In this case, we were unable to amplify the 3¢ part of exon 5 using
a primer within exon 5 (for which the priming site has been shown
to be present) and all combinations of exon 5 primers given in
Table 2 or in Steck et al (1997). All other PTEN PCR products
amplified successfully from the same DNA preparation, and the
missing PCR product, were amplified from normal tissue taken
from the same section. Two tumours showed non-coding intronic
sequence variations, one of which occurred in both tumour and
normal tissue. This tumour also showed a sequence variation
resulting in a silent codon change (Table 3).
To determine whether the PTEN sequence variations detected
in these gliomas were associated with loss of heterozygosity in
chromosome 10q, microsatellite marker analysis using markers
D10S1687, D10S583, AFMA086WG9 and D10S2491 was carried
out. All of the cases with genetic variants of PTEN showed allelic
loss at all informative loci tested.
In this glioma series, 11 genetic variants have been found; four
in the 13 anaplastic astrocytomas, of which three were acquired
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Figure 2 Sequence data for case 21 deletion (A) and case 35 substitution
(B). In (A) the boxed bases are those deleted. In (B) the boxed bases are the
donor splice site of exon 3; *marks the substituted base
Table 4 Mutation in the tumours in this series (n = 46) grouped according to
histopathological grade
Mutation No mutation
Gliomas
WHO grades I and II 0 19
(low grade)
P# = 0.014 [0.015*]
WHO grades III and IV 8 19
(high grade)
Astrocytic gliomas
WHO grades I and II 0 16
(low grade)
P# = 0.0175 [0.035*]
WHO grades III and IV 8 19
(high grade)
Adult astrocytic gliomas
WHO grades I and II 0 14
(low grade)
P# = 0.035 [0.04*]
WHO grades III and IV 8 19
(high grade)
#P-values by Fisher–Irwin exact test (two-tailed probabilities). Because of the
limited sensitivity associated with direct sequence analysis, mutation, if
present, in samples with < 50% tumour cells may not be detected.
Probabilities marked* have been calculated omitting the two low grade
tumours with a neoplastic cell population of 50% or less.and could affect the encoded protein, and seven in the 14 glioblas-
tomas, of which five were acquired and could affect the encoded
protein. No mutations were detected in low grade gliomas. PTEN
mutations were found significantly more often in high grade
gliomas compared with low grade gliomas, or low grade adult
astrocytic tumours (Table 4).
DISCUSSION
This study is the first report of analysis of mutation in the recently
discovered  PTEN tumour suppressor gene in microdissected,
archival tissues. We have identified eight acquired mutations that
could affect the encoded protein in 0/2 pilocytic astrocytomas, 0/2
oligoastrocytomas, 0/1 oligodendroglioma, 0/14 astrocytomas,
3/13 (23%) anaplastic astrocytomas and 5/14 (36%) glioblast-
omas. Six of these have not been reported previously.
All eight mutations were within the region of highest homology
between the PTEN gene and the genes for tensin and auxilin. In
contrast to previous reports of mainly nonsense or frameshift
mutations in this region, resulting in truncation of PTEN protein
(Parsons, 1998), we have found predominantly missense substitu-
tions. Only one of the mutations, a missense substitution, was
found in the putative phosphatase domain of PTEN.
As found for the majority of other PTEN mutations, DNA
sequence changes that could affect the encoded PTEN protein
were only found in association with allelic loss of chromosome
10q. Most of the mutations in this study are single base substitu-
tions. Two of these are in codons not previously shown to be
mutated and two are in a region spanning codons 170–173. There
are already 12 reported mutations in this region, seven of which
were seen in glioblastomas, suggesting that this region may be a
mutational ‘hot-spot’. Only one mutation reported here, in case 35,
is believed to result in altered splicing of the PTEN mRNA. This
substitution of A for G, five bases downstream of exon 3, has been
reported previously in one Cowdens syndrome family (Marsh et
al, 1998). Furthermore, a similar splice site mutation has been
found in intron 4 of PTEN in another glioblastoma (Böstrom et al,
1998). Mutation or deletion at this position resulted in deletion of
exon 4, causing a frameshift-induced termination (Böstrom et al,
1998).
In contrast to other studies of the PTEN gene in gliomas, direct
sequence analysis of PCR products from microdissected tissue is
the most precise method for mutation detection, is associated with
fewer false negatives than mutation screening methods (Nollau
and Wagener, 1997), increases the sensitivity of detection by
enrichment of the neoplastic cell population and enables molecular
genetic changes to be related precisely to histology. However, this
technique does not allow detection of extensive homozygous dele-
tions, which have been reported to be present in 3–12% of high
grade gliomas (Wang et al, 1997; Böstrom et al, 1998), or mutation
in minor sub-populations of cells. In this study, mutation, if present
in the majority of tumour cells, would be detected in all but two of
the cases analysed. The two exceptions were from low grade,
poorly cellular tumours.
Although mutation in the PTEN gene has now been investigated
in over 250 glioblastomas, PTEN mutations have so far only been
reported in three out of 19 anaplastic astrocytomas (Liu et al, 1997;
Rasheed et al, 1997; Chiariello et al, 1998). Combining our results
with other studies gives an incidence of PTEN mutation in
anaplastic astrocytomas of 19% (6/32). Other investigations of
PTEN mutation in gliomas, which used snap-frozen tissue for
analysis and preselection by LOH in chromosome 10q and/or
mutation screening methods, reported PTEN mutation 9–30% of
glioblastomas (Liu et al, 1997, Rasheed et al, 1997; Sakurada et al,
1997, 1998; Steck et al, 1997; Böstrom et al, 1998; Chiariello et al,
1998). The incidence of PTEN mutation in the glioblastomas
analysed in this study was similar to that reported by Wang et al
(1997) who also used direct sequence analysis but without
microdissection. Thus, for the majority of gliomas, progression to
high grade occurs in the absence of mutation in the PTEN gene.
However, in our study, as in many others, alternative mechanisms
of inactivation of the PTEN gene, such as homozygous deletion or
mutation in promotor sequences or methylation, have still to be
addressed.
In this study PTEN mutations were not detected in low grade
gliomas. In two of the high grade cases with PTEN mutation, low
grade histological features were present within the same section.
In one case, the low grade tissue was well demarcated from the
high grade region, in the second, low grade tissue was in close
proximity to a transitional region and the tumour was highly infil-
trative. In initial experiments, we have been unable to detect muta-
tion in samples microdissected from low grade areas in the former.
Mutation was absent or present only to a minor extent in the low
grade samples from the latter (data not given). These observations
support the hypothesis that mutation in the PTEN gene may be
related to the transition from low grade to higher grade. We are
currently investigating further the association of mutation in the
PTEN gene with histology in these cases.
Of the cases that had PTEN mutations, all but one were initially
classified as either anaplastic astrocytomas or glioblastomas.
However, one case with PTEN mutation, a biopsy with only a
small amount of tissue available, showed some mitosis, no
necrosis and minimal capillary endothelial hyperplasia.
Histopathological re-review placed this tumour as ‘lower end of
the anaplastic scale’, indicating that mutation in the PTEN gene
can be present in tissues featuring subtle anaplastic changes.
Histopathological grading of gliomas is well recognized to be
difficult for some cases, especially when diagnosis is based on
small amounts of biopsy material which may not be representative
of the tumour as a whole. Molecular genetic analysis for mutation
in genes such as PTEN may prove to be diagnostically useful in the
future.
This study was designed to investigate the relationship of PTEN
mutation to histology; survival information is, however, available
for the majority of cases investigated. In this very limited series,
although the eight patients with high grade tumours with PTEN
mutations likely to affect the encoded protein had shorter survival
than 17 patients with high grade tumours without PTEN mutation,
log rank analysis of the Kaplan–Meier plot showed no significant
difference (P = 0.139). Only one other study has reported survival
information for gliomas, also with limited conclusions because of
low patient numbers. Rasheed et al (1997) reported no obvious
relationship between PTEN mutation and survival, but observed a
trend for PTEN mutation to occur in an older group of patients. In
our small series there is no obvious relationship between patient
age and the presence of PTEN mutation. The PTEN gene is now
becoming well established as an important tumour suppressor gene
in the development of many malignancies. These observations
highlight the need for further research to determine its prognostic
significance particularly in gliomas.
PTEN mutation in gliomas 1547
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